Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Ana Raygoza

Physician Assistant San Antonio, TX Physician Assistant

NPI 1437313913 CMS profile 10445843

520 E Euclid Ave, San Antonio, TX 78212

Open in the dashboard

General payments

$9,738

599 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ana Raygoza of San Antonio, TX is reported in the CMS Open Payments database as having received $9,738 across 599 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,933 108
2024 General $2,063 115
2023 General $1,716 113
2022 General $2,361 144
2021 General $1,665 119

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ana Raygoza
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Ana Raygoza were reported at $1,933. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Ana Raygoza Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,665 $132 $37–$438 $132
2022 $2,361 $155 $48–$522 $149
2023 $1,716 $167 $52–$557 $160
2024 $2,063 $178 $55–$600 $164
2025 $1,933 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,744 176 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,879 116 payments
  3. Janssen Biotech, Inc. $1,297 84 payments
  4. RedHill Biopharma Inc. $492 44 payments
  5. Lilly USA, LLC $354 18 payments
  6. QOL Medical, LLC $325 16 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $301 15 payments
  8. Pfizer Inc. $258 15 payments
  9. Nestle HealthCare Nutrition Inc. $245 16 payments
  10. Gilead Sciences, Inc. $217 11 payments
  11. Other $1,624 88 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $9,738 599 payments
Products named General payments · program years 2021–2025
  1. XIFAXAN $1,563 95 payments
  2. MAVYRET $780 58 payments
  3. STELARA $779 54 payments
  4. CREON $657 31 payments
  5. RINVOQ $629 46 payments
  6. TREMFYA $547 32 payments
  7. LINZESS $511 35 payments
  8. SKYRIZI $373 27 payments
  9. ZENPEP $325 21 payments
  10. Talicia $322 28 payments
  11. Other $4,079 239 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 34 drugs

Part D claims

2,044

Median for Physician Assistant: 241

Drug cost

$470,271

Median for Physician Assistant: $4,110

Branded share of claims

27.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 134 $113,661
Creon Lipase/Protease/Amylase Brand 23 $103,684
Zenpep Lipase/Protease/Amylase Brand 12 $66,839
Xifaxan Rifaximin Brand 14 $42,251
Ibsrela Tenapanor Hcl Brand 20 $39,259
Trulance Plecanatide Brand 38 $23,919
Dexlansoprazole Dr Dexlansoprazole Brand 81 $17,591
Motegrity Prucalopride Succinate Brand 23 $13,682
Movantik Naloxegol Oxalate Brand 11 $7,938
Famotidine Generic 498 $5,980

The 10 drugs with the highest cost, of 34 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$33,208

Medicare's payments for the services billed

Medicare patients

261

Average age 73

Services billed

504

160 women, 101 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Diabetes 41%
Chronic kidney disease 32%
Ischemic heart disease 31%
Depression 24%
Osteoporosis 17%
COPD 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
STELARA
  • Janssen Biotech, Inc. $234
$234 — —
CREON
  • AbbVie, Inc. $205
$205 23 —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $186
$186 14 —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $172
$172 — —
OMVOH
  • Lilly USA, LLC $153
$153 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

599 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record